Shares of drugmaker Roivant Sciences spiked more than 8% on Thursday to over $10 per share after announcing results from the chronic period of the TUSCANY-2 Phase 2b study of RVT-3101, a once-monthly subcutaneously administered anti-TL1A antibody. “We were already extremely pleased by the induction data we reported in January. Our expectations for this chronic data were categorically exceeded, with significant improvements seen in patients receiving the expected Phase 3 dose across all key efficacy metrics at week 56 versus at week 14. This effect was even more pronounced in patients who are biomarker positive. We also saw that the clinical remission reported for week 14 was maintained in the vast majority of patients, which, if confirmed in Phase 3, has the potential to transform the treatment paradigm for IBD – currently marked by low remission rates and poor persistence of effect,” said Matt Gline, CEO of Roivant.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ROIV:
- Roivant Rises on Promising Phase 2b Data in Ulcerative Colitis
- Roivant Sciences reports chronic period data for RVT-3101 from TUSCANY-2 study
- Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period
- Roivant to Host Investor Call at 8:00 AM ET on Thursday, June 22 to Review Results from the Chronic Period of TUSCANY-2, a Large Global Phase 2b Study of RVT-3101 (Anti-TL1A Antibody) in Ulcerative Colitis